Pfizer (NYSE:PFE) hasn't had a good year, having both underperformed rivals such as Johnson & Johnson (NYSE:JNJ), and Merck (NYSE:MRK), as well as the S&P 500.
PFE Total Return Price data by YCharts
3 Reasons Pfizer Is A Screaming Buy Right Now
-
Sponsored -
Agency/Corporate ProgramCheck Raises $35 million in Series B
Check, a first-of-its-kind payroll infrastructure startup whose mission is to make paying people simple, announced its public launch today with $35 million in Series B funding from Stripe and Thrive Capital.
MG+M Elevates New York Attorney Karina Murski to Partner
MG+M The Law Firm (MG+M) is pleased to announce that it has elevated New York attorney Karina E. Murski
Einhorn Barbarito Frost & Botwinick Elevates Matthew Rheingold to Partner
Einhorn, Barbarito, Frost & Botwinick, PC, is pleased to announce that Matthew S. Rheingold has been elevated from
Einhorn Barbarito Frost & Botwinick Partners Thomas Snyder and Matheu Nunn Named as Co-Chairs of Firm’s Family/Matrimonial Practice
Einhorn, Barbarito, Frost & Botwinick, PC, is pleased to announce that partners Thomas J. Snyder and Matheu D. Nunn
TRUSTED BY
THESE PARTNERS:
